LIGAND PHARMACEUTICALS INC Quarterly Goodwill in USD from Q4 2010 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.
Summary
Ligand Pharmaceuticals Inc quarterly Goodwill history and growth rate from Q4 2010 to Q3 2024.
  • Ligand Pharmaceuticals Inc Goodwill for the quarter ending September 30, 2024 was $105M, a 1.43% increase year-over-year.
Goodwill, Quarterly (USD)
Goodwill, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q3 2024 $105M +$1.48M +1.43% Sep 30, 2024 10-Q 2024-11-08
Q2 2024 $105M -$423K -0.4% Jun 30, 2024 10-Q 2024-08-07
Q1 2024 $105M -$423K -0.4% Mar 31, 2024 10-Q 2024-05-08
Q4 2023 $103M -$2.3M -2.18% Dec 31, 2023 10-Q 2024-11-08
Q3 2023 $104M -$77.4M -42.7% Sep 30, 2023 10-Q 2023-11-09
Q2 2023 $106M -$75.5M -41.7% Jun 30, 2023 10-Q 2023-08-09
Q1 2023 $106M -$75.5M -41.7% Mar 31, 2023 10-Q 2023-05-08
Q4 2022 $106M $0 0% Dec 31, 2022 10-K 2024-02-29
Q3 2022 $181M -$8.98M -4.72% Sep 30, 2022 10-Q 2022-11-08
Q2 2022 $181M -$9.31M -4.89% Jun 30, 2022 10-Q 2022-08-09
Q1 2022 $181M -$9.31M -4.89% Mar 31, 2022 10-Q 2022-05-09
Q4 2021 $106M -$84M -44.3% Dec 31, 2021 10-K 2023-02-28
Q3 2021 $190M +$88M +86.2% Sep 30, 2021 10-Q 2021-11-09
Q2 2021 $191M +$87.1M +84.3% Jun 30, 2021 10-Q 2021-08-03
Q1 2021 $191M +$96.2M +102% Mar 31, 2021 10-Q 2021-05-06
Q4 2020 $190M +$94.4M +99.2% Dec 31, 2020 10-K 2022-02-28
Q3 2020 $102M +$8.62M +9.22% Sep 30, 2020 10-Q 2020-11-06
Q2 2020 $103M +$15.4M +17.5% Jun 30, 2020 10-Q 2020-08-07
Q1 2020 $94.3M +$7.53M +8.68% Mar 31, 2020 10-Q 2020-05-08
Q4 2019 $95.2M +$8.58M +9.91% Dec 31, 2019 10-K 2021-02-24
Q3 2019 $93.5M +$7.55M +8.79% Sep 30, 2019 10-Q 2019-11-08
Q2 2019 $88M +$2.04M +2.37% Jun 30, 2019 10-Q 2019-08-08
Q1 2019 $86.8M +$848K +0.99% Mar 31, 2019 10-Q 2019-05-09
Q4 2018 $86.6M +$687K +0.8% Dec 31, 2018 10-K 2020-02-27
Q3 2018 $86M +$13.8M +19% Sep 30, 2018 10-Q 2018-11-08
Q2 2018 $86M +$13.8M +19% Jun 30, 2018 10-Q 2018-08-08
Q1 2018 $86M +$13.8M +19% Mar 31, 2018 10-Q 2018-05-09
Q4 2017 $86M +$13.8M +19% Dec 31, 2017 10-K 2019-02-28
Q3 2017 $72.2M -$152K -0.21% Sep 30, 2017 10-Q 2017-11-09
Q2 2017 $72.2M -$153K -0.21% Jun 30, 2017 10-Q 2017-08-09
Q1 2017 $72.2M -$790K -1.08% Mar 31, 2017 10-Q 2017-05-09
Q4 2016 $72.2M +$60M +490% Dec 31, 2016 10-K 2018-03-01
Q3 2016 $72.4M +$60.1M +491% Sep 30, 2016 10-Q 2016-11-15
Q2 2016 $72.4M +$60.1M +491% Jun 30, 2016 10-Q/A 2016-11-15
Q1 2016 $73M +$60.8M +496% Mar 31, 2016 10-Q/A 2016-11-15
Q4 2015 $12.2M $0 0% Dec 31, 2015 10-K 2017-02-28
Q3 2015 $12.2M $0 0% Sep 30, 2015 10-Q 2015-11-09
Q2 2015 $12.2M $0 0% Jun 30, 2015 10-Q 2015-08-05
Q1 2015 $12.2M $0 0% Mar 31, 2015 10-Q 2015-05-11
Q4 2014 $12.2M $0 0% Dec 31, 2014 10-K/A 2016-11-15
Q3 2014 $12.2M $0 0% Sep 30, 2014 10-Q 2014-10-31
Q2 2014 $12.2M $0 0% Jun 30, 2014 10-Q 2014-08-05
Q1 2014 $12.2M $0 0% Mar 31, 2014 10-Q 2014-05-07
Q4 2013 $12.2M $0 0% Dec 31, 2013 10-K 2015-02-23
Q3 2013 $12.2M $0 0% Sep 30, 2013 10-Q 2013-11-08
Q2 2013 $12.2M $0 0% Jun 30, 2013 10-Q 2013-08-01
Q1 2013 $12.2M $0 0% Mar 31, 2013 10-Q 2013-05-08
Q4 2012 $12.2M $0 0% Dec 31, 2012 10-K/A 2014-12-12
Q3 2012 $12.2M Sep 30, 2012 10-Q 2012-11-14
Q2 2012 $12.2M Jun 30, 2012 10-Q/A 2012-11-14
Q1 2012 $12.2M Mar 31, 2012 10-Q/A 2012-11-14
Q4 2011 $12.2M +$11.5M +1648% Dec 31, 2011 10-K 2013-03-14
Q4 2010 $700K Dec 31, 2010 10-K/A 2012-11-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.